Peer Support Impact on Therapeutic Adherence in Patients With Multiple
Peer Support Impact on Therapeutic Adherence in Patients With Multiple Sclerosis: a Mixed Methods Randomized Controlled Trial Pilot Study
What it found
No result yet.
What was tested
Treatment tested
- Peer support
What it measured
Main measures
Therapeutic adherence
6 months
Walking and mobilityQuality of life (reported by participants)
Other measures (4)
Therapeutic compliance
6 months
Quality of life (reported by participants)Participants' quality of life
6 months
Quality of life (reported by participants)Emotional wellbeing
6 months
Mood and sleepSocial support
6 months
Quality of life (reported by participants)
Who could take part
Relapsing MS · 18 to 95
Show the full criteria
Inclusion criteria
* Adult patients * With relapsing-remitting MS according to 2017 revised Mc Donald criteria * Attending medical consultation at Nantes University Hospital Neurology Department * For whom background drug therapy is needed (oral or injectable) * Who gave consent to participate in trial
Exclusion criteria
* Primary-progressive or secondary-progressive MS patients * Patients under protection of vulnerable adults measure or convicted * Patients not fluent in French * Patients with severe cognitive impairment, who may find difficult filling out questionnaires properly * Patients with a risk of follow-up interruption (move, nomadism…)
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
A mixed methods randomized controlled trial pilot study to assess peer support impact on relapsing-remitting multiple sclerosis patients' therapeutic adherence.
Papers
Loading reviews and guidelines…
History
Started
May 2023
Main results due
Dec 2026
Finished
Dec 2026